UNLEASHING THE PROMISE OF T-CELL THERAPIES.
Cutting-edge science. A fresh approach.
Allogeneic T-cell therapies can be readily available for rapid delivery within days.
Efficient, robust process with the ability to produce over a thousand doses from one healthy donor.
Highly versatile platform
Potential application for a wide range of disease-causing viral and non-viral targets.
We’re developing a pipeline of firsts.
Our investigational T-cell therapies target difficult-to-treat Epstein-Barr virus (EBV)-driven conditions, including certain cancers and multiple sclerosis, as well as a wide range of non-EBV-associated diseases. We’re the first company ever to receive an approval for an allogeneic T-cell immunotherapy.
In the News
February 29, 2024Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy READ MORE
February 14, 2024Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis READ MORE
January 31, 2024Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology READ MORE